David A. Brenner, M.D.

David Brenner, M.D.

David A. Brenner, M.D.

President and Chief Executive Officer

David Brenner's Research Focus

Liver Diseases
Apoptosis and Cell Death

Clinical Trials

Alpha-1 Antitrypsin Deficiency Adult Liver Study
Start Date: Dec 2013
Estimated Completion Date: Sep 2023
Recruitment Status: Recruiting
Condition(s): Alpha-1 Antitrypsin Deficiency


Research Activities and Funding

  • Microbiome as Therapeutic Target in Alcoholic Hepatitis
    NIHU01AA021856Jun 1, 2013 - May 31, 2019
    Role: Principal Investigator
  • The Southern California Research Center for ALPD and Cirrhosis
    NIHP50AA011999Jan 1, 1999 - Dec 31, 2023
    Role: Co-Investigator
  • Gastroenterology Research Training
    NIHT32DK007737Aug 1, 1996 - Jun 30, 2026
    Role: Principal Investigator
  • Molecular and Cellular Pathogenesis in Alcoholism
    NIHP60AA011605Dec 1, 1997 - Nov 30, 2017
    Role: Co-Investigator
  • Molecular Mechanisms by which TNFalpha Modulates Fibrosis
    NIHR01GM041804Apr 1, 1989 - Dec 31, 2014
    Role: Principal Investigator
  • Integrated Center for InVivo Microscopy
    NIHP41RR005959Sep 1, 1990 - Jun 30, 2013
    Role: Co-Investigator
See more
  • The Role of Inflammation and Stroma in Digestive Cancer
    NIHU54CA126513Sep 30, 2006 - Sep 21, 2011
    Role: Co-Investigator
  • Angiotensin II and NADPH Oxidase in Hepatic Fibrosis
    NIHR01DK072237Sep 15, 2005 - Jun 30, 2011
    Role: Principal Investigator
  • Hepatic Stellate Cell Activation induced by Hepatitis C Virus
    NIHR01AA015055Sep 30, 2003 - Aug 31, 2009
    Role: Principal Investigator
  • Cond. Acceptance Post-Bac. Prog. Scholarship Fund
    NIHS22MD000227Sep 30, 2002 - Sep 29, 2005
    Role: Principal Investigator
  • Molecular Pathogenesis of Apoptosis in Liver Cells
    NIHP01DK059340Sep 21, 2001 - May 31, 2006
    Role: Co-Investigator
  • Oncogenic K-Ras Induction of Gastrin Gene Transcription
    NIHR01DK055686Aug 15, 2000 - Jul 31, 2006
    Role: Principal Investigator
  • Gene Technology Therapy and Alcohol-Induced Fibrosis
    NIHR01AA012586Sep 23, 1999 - Jun 30, 2003
    Role: Principal Investigator
  • Molecular and Cellular Pathogenesis in Alcoholism
    NIHP50AA011605Dec 1, 1997 - Nov 30, 2002
    Role: Co-Investigator
  • Rat Model of Alcoholic Pancreatitis
    NIHR03AA011226Apr 1, 1997 - Mar 31, 1999
    Role: Principal Investigator
  • Gene Therapy for Liver Diseases
    NIHR13DK047627Jan 20, 1994 - Oct 31, 1994
    Role: Principal Investigator
  • Molecular Defects in Protoporphyria
    NIHR01DK047361May 1, 1993 - May 31, 2004
    Role: Principal Investigator
  • Function of Nuclear Oncogenes in Cancer Cells
    NIHP01CA050528Sep 8, 1989 - Jan 31, 1998
    Role: Co-Investigator
  • Molecular Defect in Protoporphyria
    NIHR29DK039996Apr 1, 1988 - Mar 31, 1993
    Role: Principal Investigator
  • General Clinical Research Center
    NIHM01RR000827Mar 1, 1974 - Nov 30, 2010
    Role: Principal Investigator

David Brenner's Bio

Dr. David A. Brenner is a distinguished physician-scientist and leader in the field of gastroenterological research and has been in practice for more than 20 years.


Education and Training

1988: Fellowship, Gastroenterology, UC San Diego
1986: Fellowship, Genetics & Biochemistry, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD
1985: Intern & Residency, Internal Medicine, Yale University
1979: M.D., Medicine, Yale University
1975: B.S., Biology, Yale University


Awards, Honors and Recognition

2005: Fellow (FACP), American College of Physicians
1986: Bomedical Scholar, Pew Foundation


Other Appointments and Memberships

Alcoholic Beverage Medical Research Foundation
American Society for Clinical Investigation
Association of American Physicians
American College of Physicians
American Gastroenterological Association
American Clinical and Climatological Association

scientist at work


The Role of Mesothelin in Activation of Portal Fibroblasts in Cholestatic Liver Injury.

Nishio T, Koyama Y, Fuji H, Ishizuka K, Iwaisako K, Taura K, Hatano E, Brenner DA, Kisseleva T

Biology (Basel) 2022 Oct 28 ;11(11)

Multiplex short tandem repeat profiling of immortalized hepatic stellate cell line Col-GFP HSC.

Meurer SK, Brenner DA, Weiskirchen R

PLoS One 2022 ;17(9):e0274219

Metabolic Injury of Hepatocytes Promotes Progression of NAFLD and AALD.

Carvalho-Gontijo R, Han C, Zhang L, Zhang V, Hosseini M, Mekeel K, Schnabl B, Loomba R, Karin M, Brenner DA, Kisseleva T

Semin Liver Dis 2022 Aug ;42(3):233-249

Aberrant iron distribution via hepatocyte-stellate cell axis drives liver lipogenesis and fibrosis.

Gao H, Jin Z, Bandyopadhyay G, Wang G, Zhang D, Rocha KCE, Liu X, Zhao H, Kisseleva T, Brenner DA, Karin M, Ying W

Cell Metab 2022 Aug 2 ;34(8):1201-1213.e5

MiR-690 treatment causes decreased fibrosis and steatosis and restores specific Kupffer cell functions in NASH.

Gao H, Jin Z, Bandyopadhyay G, Cunha E Rocha K, Liu X, Zhao H, Zhang D, Jouihan H, Pourshahian S, Kisseleva T, Brenner DA, Ying W, Olefsky JM

Cell Metab 2022 Jul 5 ;34(7):978-990.e4

CRIg on liver macrophages clears pathobionts and protects against alcoholic liver disease.

Duan Y, Chu H, Brandl K, Jiang L, Zeng S, Meshgin N, Papachristoforou E, Argemi J, Mendes BG, Wang Y, Su H, Sun W, Llorente C, Hendrikx T, Liu X, Hosseini M, Kisseleva T, Brenner DA, Bataller R, Ramachandran P, Karin M, Fu W, Schnabl B

Nat Commun 2021 Dec 9 ;12(1):7172

Show All Publications